title: Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
abstract: OBJECTIVE
  To evaluate the early efficacy of the alpha(1A)-adrenoceptor selective drug, silodosin, for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
  
  
  METHODS
  A total of 68 patients with an International Prostate Symptom Score (IPSS) of >==8 and a Quality of Life (QOL) index of >==2 were included. Changes in the IPSS and QOL index were evaluated before and after 1, 2, 3, 4, 5, 6, 7, 14, and 28 days of twice daily oral administration of 4 mg silodosin. Next, changes in IPSS subscores as well as voiding, storage, and post micturition symptoms were assessed. Changes in total IPSS based on symptom severity were also determined.
  
  
  RESULTS
  Total IPSS and QOL index improved significantly from 19.38 +/- 7.46, 4.68 +/- 1.07 at baseline to 15.81 +/- 7.40, 4.22 +/- 1.30 at day 1. The subscores of voiding, storage, and post micturition symptoms were significantly decreased from 8.93 +/- 3.95, 7.97 +/- 3.88, and 2.49 +/- 1.70 at baseline to 7.28 +/- 4.09, 6.52 +/- 3.47, and 2.02 +/- 1.56 at day 1, respectively. This trend continued throughout the study. Regardless of severity, total IPSS were significantly decreased at day 1 and maintained throughout the study.
  
  
  CONCLUSIONS
  Silodosin may be considered a promising treatment for benign prostatic hyperplasia/lower urinary tract symptom patients.
authors.affiliation: Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Takao
authors.forename: Akira
authors.initials: A
authors.lastname: Tsujimura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kiuchi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Matsuoka
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Miyagawa
authors.forename: Norio
authors.initials: N
authors.lastname: Nonomura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Iwasa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kameoka
authors.forename: Hideya
authors.initials: H
authors.lastname: Kuroda
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Matsumiya
authors.forename: Kinya
authors.initials: K
authors.lastname: Uchida
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Akihiko
authors.initials: A
authors.lastname: Okuyama
mesh_terms: D018674:Adrenergic Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications*; D053448:Prostatism / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D018674:Adrenergic Antagonists; D007211:Indoles; C095285:silodosin